Adults with a history of using classic psychedelics report lower levels of anxiety and depression than non-users, but this link is evident only among younger age groups, according to an observational survey study led by researchers at Durham University. The investigation evaluated survey responses from 1,088 adult participants aged 18 to 55 and older, discovering that the associations between substance use and mental health weakened as participant age increased and were absent among older demographics.

Published in the journal Scientific Reports, the study was conducted amid growing scientific interest regarding the therapeutic potential of psychedelic-assisted treatments for psychiatric conditions including depression and anxiety. PhD researcher Giammarco Di Gregorio led the project under the supervision of Dr Marco Bocchio and Dr Michael Lengieza at Durham University. Study participants responded to inquiries concerning their lifetime use of psychedelic substances while completing established measurement scales evaluating anxiety, depression, personal wellbeing, and overall life satisfaction.

The observed mental health associations differed markedly across specific generational brackets within the surveyed cohort. Individuals in their twenties and early thirties who reported using classic psychedelics, such as psilocybin or LSD, exhibited lower anxiety and depression scores compared to non-users of similar ages. However, this statistical relationship progressively declined across advancing age brackets, showing no persistent mental health differences between classic psychedelic users and non-users among the older adults surveyed.

Statistical analyses demonstrated that these age-moderated patterns remained consistent after accounting for several confounding usage characteristics. Researchers adjusted their models for the frequency with which individuals consumed psychedelics, the time elapsed since their most recent use, and their typical dosage amounts. Even with these consumption variables controlled, age continued to moderate the measured relationship between classic psychedelic consumption and reported symptoms of depression and anxiety.

To isolate whether the findings reflected general tendencies toward altering consciousness, the researchers grouped participants into distinct categories: those who used classic psychedelics, those who used non-classic substances such as ketamine or MDMA, individuals who consumed both categories, and non-users. Dr Marco Bocchio explained that incorporating a comparison cohort of non-classic psychedelic users helped test whether the observations were specific to classic psychedelics rather than broad behavioral differences among people drawn to psychoactive compounds and altered states.

The study authors suggested that variations in subjective experiences might contribute to the observed age divergence. Di Gregorio noted that younger individuals tend to report more intense, mystical-type experiences while using psychedelics, and the survey data indicated that these mystical experiences helped explain the stronger link to lower anxiety and depression in younger adults. Bocchio highlighted that surveying more than 1,000 individuals across a broad age range enabled the team to identify age-related dynamics that are often challenging to detect in clinical trials.

The authors emphasized that their observational design relies entirely on self-reported data and cannot establish a causal relationship between psychedelic consumption and mental health outcomes. Because individuals reported past behaviors and current symptoms retrospectively, the study cannot verify whether psychedelic substances directly produced improvements in psychological wellbeing or if other unmeasured factors influenced both substance use and mental health states.

The research team intends to build upon these cross-sectional findings by conducting longer-term investigations that track participants before and after psychedelic experiences. Such prospective tracking aims to determine whether age-related patterns persist in controlled clinical environments and may ultimately assist clinicians in evaluating which demographic populations could derive the greatest benefit from psychedelic-assisted therapies.

Lead author Giammarco Di Gregorio pointed to the role of subjective effects during substance use as a key factor in the findings. “Age remains a relatively underexplored factor in psychedelic research,” Di Gregorio said. “There’s growing evidence that younger people tend to have more intense, mystical-type experiences while on psychedelics. Our study suggests this may matter for mental health. The link between classic psychedelic use and lower anxiety and depression was strongest in younger adults and faded with age, and the mystical experiences younger users reported helped to explain that pattern.”

Co-supervisor Dr Marco Bocchio highlighted the methodological rationale for distinguishing substance types within the sample. “A novelty of our study was the inclusion of a comparison group of people who had used ‘non classic psychedelics’, such as ketamine or MDMA, but not classic psychedelics,” Bocchio stated. “This helped us test whether the patterns we observed were specific to classic psychedelics, rather than reflecting broader differences between people who are drawn to psychoactive substances and altered states of consciousness.”

Bocchio also underscored how the size and age range of the dataset informed their conclusions. “One of the strengths of this study is that it allowed us to examine psychedelic use and mental health associations in a large sample with a broad age range, which can be difficult to achieve in clinical trials,” he said. “By analysing data from more than 1,000 participants, we were able to identify age-related patterns that might otherwise be missed. While our study cannot establish cause and effect, it provides an important starting point for understanding how age might shape the relationship between psychedelic experiences and mental health, and offers clues that can be explored in future clinical research.”

Subject of Research: Age-related associations between classic psychedelic use and mental health

Article Title: Age may influence links between psychedelic use and mental health

Article References: Age may influence links between psychedelic use and mental health. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: psychedelics, mental health, anxiety, depression, Durham University, psilocybin, LSD, observational study, influence, links, between, psychedelic